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Abstract Although there are international guidelines
orienting physicians on how to manage patients with
acromegaly, such guidelines should be adapted for use in
distinct regions of the world. A panel of neuroendocrinol-
ogists convened in Mexico City in August of 2007 to
discuss speciﬁc considerations in Latin America. Of major
discussion was the laboratory evaluation of acromegaly,
which requires the use of appropriate tests and the adoption
of local institutional standards. As a general rule to ensure
diagnosis, the patient’s GH level during an oral glucose
tolerance test and IGF-1 level should be evaluated. Fur-
thermore, to guide treatment decisions, both GH and IGF-1
assessments are required. The treatment of patients with
acromegaly in Latin America is inﬂuenced by local issues
of cost, availability and expertise of pituitary neurosur-
geons, which should dictate therapeutic choices. Such
treatment has undergone profound changes because of the
introduction of effective medical interventions that may be
used after surgical debulking or as ﬁrst-line medical ther-
apy in selected cases. Surgical resection remains the
mainstay of therapy for small pituitary adenomas (mic-
roadenomas), potentially resectable macroadenomas and
invasive adenomas causing visual defects. Radiotherapy
may be indicated in selected cases when no disease control
is achieved despite optimal surgical debulking and medical
therapy, when there is no access to somatostatin analogues,
or when local issues of cost preclude other therapies. Since
not all the diagnostic tools and treatment options are
available in all Latin American countries, physicians need
to adapt their clinical management decisions to the avail-
able local resources and therapeutic options.
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Introduction
In August 2007, a panel of neuroendocrinologists from
Latin America, the United States of America and the
United Kingdom convened in Mexico City to discuss the
diagnosis, treatment and follow-up of patients with acro-
megaly, with a speciﬁc focus on Latin America. One of the
greatest challenges in providing consensus recommenda-
tions in this region is the diversity in this large population
of more than 550 million. Furthermore, a range of man-
agement approaches may not be available for many
patients with acromegaly and the feasibility and cost
should be considered in the implementation of local
guidelines. Therefore, this meeting was conducted with the
aim of providing recommendations for the management of
patients with acromegaly in Latin America, and this review
highlights the main conclusions reached during this
meeting.
Diagnostic criteria
The panel discussed the criteria used to make a diagnosis of
acromegaly and the clinical approaches in cases where a
discrepancy between growth hormone (GH) and insulin-
like growth factor-1 (IGF-1) measurements are seen.
According to the diagnostic criteria proposed at the Cortina
consensus, a random GH level lower than 0.4 lg/l and an
IGF-1 level within the age- and sex-matched normal range
excludes the diagnosis of acromegaly in a patient with no
other concurrent illness [1]. If there is clinical suspicion of
acromegaly and either of these levels are not achieved, an
oral glucose tolerance test (OGTT) should be performed
with 75 g of oral glucose, with subsequent measurements
of glucose and GH every 30 min over 2 h; a fall in GH
level to B1 lg/l and a normal IGF-1 level excludes the
diagnosis of acromegaly. The group acknowledged the fact
that with the currently used ultrasensitive GH assays, a
normal GH suppression by glucose is considerably below
1 lg/l and speculated about the appropriateness of lower-
ing the cutoff to 0.6 lg/l.
Despite the advances in biochemical assays and the
deﬁnition of cutoff levels for both GH and IGF-1, major
limitations in the diagnostic assessment of acromegaly still
exist [2]. Several factors make the biochemical diagnosis of
acromegaly challenging, including the pulsatile nature of
GH secretion, the sensitivity of GH secretion to sleep, and
changes in the secretion of the hormone according to the
age and nutritional status of the patient [3]. Assessment of
GH and IGF-1 levels are also made difﬁcult by the lack of
uniformity in reference standards and analysis [4], which
result in poor reproducibility and wide variation, in par-
ticular for IGF-1 [5–7], and make the diagnosis of acro-
megaly more challenging. Indeed, several authors have
found an overlap between the biochemical results in heal-
thy volunteers and in patients with acromegaly if the cri-
terion of a GH nadir of\1 lg/l during an OGTT was used
[8, 9].
Given the difﬁculties in assessing GH and IGF-1 levels,
the panel recommended that random GH levels should not
be used as a diagnostic tool in acromegaly. Ideally, each
laboratory should attempt to standardize age- and sex-
matched IGF-1 reference values and establish its own
cutoff point. Also, an attempt should be made to certify
assays with appropriate biological standards. Notably, even
if IGF-1 levels are very high and the clinical picture of
acromegaly is clear, GH evaluation during OGTT at
diagnosis could be useful, since follow-up management
should be taken into consideration. Furthermore, the panel
supported the use of an OGTT (using a GH nadir of\1 lg/l)
in patients where there was a discrepancy between IGF-1
levels and the clinical picture. The panel also highlighted
that extreme caution should be exercised when employing
this test in patients exhibiting glucose intolerance.
First-line therapy
The panel addressed the issue of when treatment with
somatostatin analogues or surgery should be considered.
Generally, surgery is indicated for GH-secreting microad-
enomas, resectable macroadenomas and for decompression
of vital structures, particularly the optic tracts [3]. While
cure rates with surgical resection can be as high as 90% in
patients with a microadenoma and approximately 50% in
patients harboring a macroadenoma, they are lower if the
adenoma is invasive [10, 11]. Despite the known beneﬁts
of transsphenoidal resection by experienced surgeons for
small pituitary adenomas [12], patients with larger adeno-
mas (e.g. [20 mm) and a preoperative GH level greater
than 50 lg/l may also require medical and, sometimes,
radiation therapy to control GH hypersecretion [10, 13].
Many patients with acromegaly in Latin America present
with large, often inoperable tumors that are not conﬁned to
the sella turcica and therefore cannot be cured by surgery
alone.
First-line medical therapy has improved over the last
decade, and ﬁrst-line therapy with somatostatin analogues
is now considered a viable alternative to surgery in selected
patients [14]. Success rates for octreotide LAR as ﬁrst-line
therapy for acromegaly have been reported to range from
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12340 to 80% for the achievement of a ‘safe’ GH level of
2–2.5 lg/l, and from 30 to 65% for the normalization of
IGF-1 [15, 16]. Although there are fewer reported studies
concerning lanreotide Autogel as ﬁrst-line therapy for
acromegaly, a recent study in which 26 newly diagnosed
patients were treated with lanreotide Autogel for 12 months
found that 58% of patients achieved a GH level B1.9 lg/l,
and 58% of patients had normalized IGF-1 [17]. In addition
to biochemical control, ﬁrst-line therapy with octreotide
LAR has been shown to signiﬁcantly reduce tumor size in
approximately 80% of patients [18, 19], and recent studies
suggest octreotide LAR can also provide long-term bio-
chemical and tumor volumetric control [20, 21]. Moreover,
a recent prospective trial including patients from Latin
America has suggested that octreotide LAR represents a
viable alternative to surgery for the primary treatment of
acromegaly [16].
Although the panel advocated the use of ﬁrst-line med-
ical therapy in patients with acromegaly, they acknowl-
edged that access to somatostatin analogues is a key issue in
Latin America, as treatment is not always subsidized by
government agencies. However, this situation varies not
only between countries but also within countries. Therefore,
health economic analyses are warranted in this region.
Physicians in Latin America should tailor appropriate
treatments or combinations for each patient based on the
clinical presentation and availability of resources (Fig. 1).
As a general rule, however, the panel recommended that
tumor resection performed by an experienced pituitary
neurosurgeon should be the ﬁrst option in patients with a
microadenoma or a resectable macroadenoma, as well as in
patients with an invasive macroadenoma and visual ﬁeld
defects. Initial surgical therapy could also be indicated for
some patients with large invasive tumors to reduce the
tumor mass (debulking) and, consequently, reduce GH and
IGF-1 levels (albeit without achieving normalization) for
the following reasons: (a) unavailability of somatostatin
analogues (which is a reality in some countries in Latin
America) and; (b) improve the response to medical treat-
ment [22, 23] and radiotherapy [24].
First-line medical therapy should be indicated for
patients who are not willing to undergo, or are not ﬁt for
surgery, as well as in those whose tumor has invaded the
cavernous sinus or in whom surgical debulking is not
feasible. For cases not falling within the above categories,
judgment is required to indicate the ﬁrst-line therapy,
taking into account the local experience and availability of
resources.
Management and optimization of treatment with
somatostatin analogues
There is now convincing evidence that octreotide LAR is a
well-tolerated and effective medical therapy for patients
with acromegaly [16, 21, 25–28]. The panel discussed the
dose that should be used and how this dose should be
modiﬁed in clinical practice. Although an acute test dose of
subcutaneous octreotide is used in some centers, [29] the
panel agreed that this acute test is generally not predictive
of a long-term response to octreotide LAR. Early dose-
ﬁnding studies of octreotide LAR suggested that one
injection of either the 20 or 30 mg dose may provide
biochemical control of the disease for up to 4 and 6 weeks,
respectively [27, 30]. More recently, it has been suggested
that the variability in individual patient responses to depot
somatostatin analogues requires individual dose titration
and careful assessment of the optimal dose and injection
interval [31–34]. Therefore, it is recommended that
patients initiate treatment with octreotide LAR 20 mg
Fig. 1 Suggested algorithm for
choosing ﬁrst-line therapy in
Latin American patients with
newly diagnosed acromegaly
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123every 28 days, with evaluation of biochemical control after
3 or 6 months. For those patients with uncontrolled disease
after 3–6 months, the dose should be increased to 30 mg
every 28 days. The maximum dose of octreotide LAR used
in clinical practice is typically 30 or 40 mg every 4 weeks.
Despite limited data on the efﬁcacy of the 40 mg dose
among patients not responding to the 30 mg dose, some
studies have suggested that increasing the dose of octreo-
tide LAR to 40 mg in these patients may result in enhanced
suppression of GH and IGF-1 levels without additional
toxicity [33, 35].
In patients well controlled with octreotide LAR (normal
serum GH and IGF-1 levels), two different approaches may
be considered. The ﬁrst is to reduce the dose (from 30 to
20 mg, or from 20 to 10 mg, for example), keeping the
same dose interval [36]. Secondly, increasing the injection
interval of octreotide LAR treatment from 4 to 6 weeks
may be feasible [37].
Similarly, lanreotide Autogel may be initiated at a dose
of 90 mg every 28 days, and then titrated up to 120 mg or
down to 60 mg every 28 days after 3–6 months depending
on the level of biochemical control. There is also some
evidence that the dose interval of lanreotide Autogel may
be extended in patients with biochemical control [38].
Despite the controversy associated with the monitoring
of patients treated with somatostatin analogue therapy, an
algorithm recently proposed by a group in Oxford, UK
used GH levels of 2.5 lg/l as an indication of biochemical
control [32]. There are many reports stating that both GH
and/or IGF-1 are important for achieving disease control
[39–43] and, as discussed, there are known limitations
regarding their measurement [3]. Because of these limita-
tions, the most reliable evaluation to conﬁrm disease con-
trol would be to assess both GH and IGF-1 values [44].
Therefore, the panel recommended using IGF-1 levels for
decisions regarding the appropriateness of dose and injec-
tion interval, GH levels (either basal or an average of 5–6 h
consecutive measurements) to monitor medical therapy,
and GH levels after OGTT to assess cure or disease control
after surgery (and when IGF-1 values and the clinical
picture are discrepant). Although a 3-month interval for
biochemical assessment was considered appropriate in
most cases, the panel emphasized that IGF-1 levels may
take longer to return to normal than GH levels.
Combining and changing medical therapy
The next issue addressed by the panel was uncontrolled
disease in patients who had received optimal doses of
somatostatin analogues and maximal surgical debulking.
Approximately one-third of patients with acromegaly trea-
ted with somatostatin analogues for prolonged periods of
time do not achieve safe levels of GH or a normalization of
serum IGF-1 levels, and such lack of control is thought to be
related to the type and density of somatostatin receptor
subtype (sst) expression in the tumor [45]. Therefore, the
panel recommendations below (Fig. 2) are applicable to
patients whose disease remains uncontrolled by maximal
somatostatin analogue therapy equivalent to monthly
octreotide LAR doses of 30 or 40 mg.
Cabergolineisadopamineagonistwithapotentandlong-
lasting action, as well as an acceptable safety proﬁle, when
compared with bromocriptine [46]. Studies of single-agent
cabergoline administered as weekly doses ranging from 1.0
to3.5 mg,havedemonstratedthatcabergolineiseffectivein
patients with and without prolactin cosecretion [46, 47].
However, it is currently unclear whether patients whose
disease is resistant to somatostatin analogue therapy should
receive cabergoline as a single agent or in combination with
Fig. 2 Suggested treatment
algorithm for Latin American
patients with acromegaly and no
disease control after maximal
surgical debulking and
somatostatin analogue therapy.
* Because pegvisomant is not
available in all Latin American
countries, radiotherapy might be
considered as an additional
treatment option for patients not
controlled after maximal doses
of somatostatin analogues and/
or cabergoline
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123a somatostatin analogue. Despite the preliminary evidence
of prolonged biochemical control in patients responding to
somatostatin analogues in whom therapy is withdrawn
[48, 49], there is anecdotal evidence of a worsening in
biochemical parameters when somatostatin analogue ther-
apy is withdrawn in patients whose disease is resistant to
somatostatin analogues. Furthermore, studies using ﬂuo-
rescent resonance energy transfer techniques have demon-
strated heterodimerization of somatostatin and dopamine
receptors, providing a biological rationale for combination
therapy trials [50]. In studies combining a somatostatin
analogue with cabergoline, 42–50% of patients achieved
normal IGF-1 levels; in addition, these studies have sug-
gestedthatsuchresponsesdonotcorrelatewithserumlevels
or tissue expression of prolactin [51–53]. Although
cabergoline is considered an attractive agent for combina-
tion therapy with octreotide LAR in patients with acro-
megaly in Latin America, at high doses there is an increased
risk of cardiac valvular abnormalities [54, 55]. Patients with
acromegaly treated with cabergoline should therefore
undergo periodic echocardiographic monitoring.
Pegvisomant, a GH receptor antagonist, represents a
further addition to the medical arsenal against acromegaly
[56]. Among patients treated primarily with surgery fol-
lowed by medical therapy and/or radiation therapy, daily
administration of pegvisomant has been shown to normalize
IGF-1 and provide clinical control of acromegaly in a large
numberofpatients[57].Inaddition,pegvisomanthasshown
activity among patients whose disease was not adequately
controlled by somatostatin analogue therapy [58, 59]. The
major disadvantages of pegvisomant are its high cost, the
fact that it does not act directly on the cause of the disease
(the pituitary tumor) and the increased risk of elevated liver
transaminase levels. Feenstra et al. [60] assessed the com-
bination of a somatostatin analogue once monthly and
pegvisomant once weekly in 26 patients with active acro-
megaly and concluded that pegvisomant was effective and
could signiﬁcantly reduce the costs of medical treatment for
acromegaly (in comparison to monotherapy with pegviso-
mant) in a proportion of patients whose disease is not fully
controlled by somatostatin analogue therapy. The feasibility
of widely implementing such a strategy in patients with
acromegaly in Latin America remains unknown, although
pegvisomant should be considered in selected cases when
resources are available. Finally, other medical options for
somatostatin analogue-resistant acromegaly may become
available in the near future, including agents with multiple
sst activity (such as pasireotide [SOM230] which has high
afﬁnity for sst1,2,3 and sst5)[ 61], agents with selective
afﬁnity for sst2 and sst5 (such as BIM-23244) [62], and
chimeric somatostatin-dopamine receptor agonists (such as
BIM-23A387) [63].
Patient follow-up after surgical resection
The panel discussion focused on the types of, and frequency
with which, laboratory and imaging studies should be car-
ried out after surgery with curative intent during follow-up.
Currently, there is considerable controversy surrounding
this issue, despite the availability of published guidelines
regarding postoperative follow-up [1, 64]. From a bio-
chemical perspective, patient classiﬁcation into ‘active
disease’ and ‘inactive disease’ categories may be more
appropriate than the use of terms such as ‘cure’, ‘remission’,
and ‘persistence’ of the disease. However, it is currently
unclear whether patient categorization based on early
evaluation, e.g. between 1 and 3 months postoperatively, is
of value, as a study in Mexico found that nearly 30% of
patients changed their initial category during follow-up
[65]. Also, it is currently uncertain whether patients with
normalIGF-1levelsandinadequateGHsuppressionafteran
OGTT are at higher risk for recurrent disease activity [66].
With regard to the classiﬁcation of active versus inactive
disease, the panel recommended assessing patients for
3 months postoperatively, using IGF-1 and GH levels as
the main indicator of disease control, as although IGF-1
levels usually stabilize within 3 months after surgery, on
rare occasions this may take up to 12 months [64]. Mea-
surement of GH levels after an OGGT should be reserved
for cases where there is some uncertainty, and discordant
biochemical results may help tailor the interval of follow-
up, which should also be dictated by patient convenience.
As a general rule, follow-up during the ﬁrst year should be
performed every 3–6 months, and at least a yearly follow-
up is indicated during the ﬁrst 3 years, but patients should
be monitored for life. In addition, lifelong evaluation is
recommended for most patients with acromegaly and
inactive disease, since recurrences as late as 10–15 years
post surgery have been reported [67, 68]. Magnetic reso-
nance imaging should be carried out 6–12 months after
surgery, and repeated only when the results of clinical and
biochemical evaluation during follow-up suggest a recur-
rence, given that this approach appears safe in patients with
adequate biochemical control of acromegaly [69].
The role of radiotherapy
In the past, radiotherapy has played an important role in the
management of patients with acromegaly. In fact, despite
some controversy regarding its efﬁcacy and safety, it is still
used in some centers, particularly in Latin America,
because of its low cost. Although the introduction of
effective medical treatment for acromegaly has reduced the
interest in radiotherapy, this is often the only available
172 Pituitary (2010) 13:168–175
123option. So rather than disqualifying radiotherapy, the panel
reviewed the available data regarding its performance as a
therapeutic tool in acromegaly. Although the efﬁcacy of
radiotherapy has been questioned by some studies [70, 71],
a retrospective study by the UK National Acromegaly
Register involving 884 patients, 111 of whom had IGF-1
levels assessed on follow-up, found a steady increase in the
proportion of patients achieving normalization of IGF-1
levels: 38% at 2 years, 50% at 5 years, and 56% at
15 years [72]. However, there are known adverse events
associated with radiotherapy in patients with acromegaly,
including visual loss or deterioration, brain necrosis and
vascular complications, secondary tumor formation, hypo-
pituitarism, and neuropsychological damage. It is note-
worthy that these adverse effects are minimized when
using modern techniques of pituitary irradiation, such as
the gamma knife. Therefore, the panel recommendation
was to consider radiotherapy for patients with acromegaly
who have persistently active disease after pituitary surgery
and fully optimized medical therapy (Fig. 2) and for those
operated, uncontrolled patients who have no access to
somatostatin analogues. The speciﬁc type of radiotherapy,
including its modality and schedule, should be guided by
local availability and expertise.
Concluding remarks
The treatment of patients with acromegaly has undergone
profound changes in the past decade, largely because of the
introduction of effective medical interventions that may be
usedasﬁrst-linetherapyinselectedcases.Althoughsurgical
resection remains the mainstay of therapy for small and
potentially resectable pituitary macroadenomas, medical
interventions represent a valuable adjunct to the therapeutic
arsenal. Radiotherapy may be indicated in selected cases
when no disease control is achieved despite optimal surgical
debulking and medical therapy, when there is no access to
somatostatin analogues, or cost considerations are para-
mount. Local issues of cost, availability and expertise of
neurosurgeons will dictate treatment choice, which should
also be tailored according to patient preferences and charac-
teristics. In addition, laboratory evaluation plays an impor-
tant role in the diagnosis and management of patients with
acromegaly, and constant improvements and standardiza-
tions of age- and sex-matched reference values are required
by local institutions. Finally, physicians in Latin America
should adapt their clinical management of patients with
acromegaly to the available diagnostic tools and therapeutic
options, in order to achieve the best treatment outcome.
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